V-safe reached 8.2 million participants, and VAERS has logged more than 1.8 million adverse event reports since it started. Across mRNA COVID-19 safety communications, most non-serious reactions begin within 1 to 2 days and typically resolve within 1 to 3 days. Risk patterns depend on dose timing, with safety signals concentrated in short windows after vaccination for specific adverse events.
Key Takeaways
- In safety communications for mRNA COVID-19 vaccines, most non-serious adverse reactions start within 1–2 days and resolve within about 1–3 days; timing distribution is summarized in clinical safety descriptions
- In the Pfizer-BioNTech BNT162b2 clinical trial publication, participants’ symptoms generally resolved within 1–2 days after dose 2; duration is described in the safety section
- In the Moderna mRNA-1273 clinical trial safety publication, the median onset of local and systemic reactogenicity after dose 2 was within 2 days; timing is described in the safety analysis
- In CDC’s surveillance, the reporting rate of myocarditis after dose 2 was 19.3 per million second doses in males aged 18–24 years (as provided in CDC tables)
- In the Vaccine Safety Datalink (VSD) analysis, the observed risk of febrile seizures was highest in the first 1–2 days after vaccination; febrile seizure risk windows were quantified in the study
- In a large cohort study of influenza vaccination, Guillain-Barré syndrome occurred at a rate of about 1–2 cases per 1 million vaccinated in the evaluated periods; study quantified excess risk
- VAERS (US) reported more than 1.8 million adverse event reports for vaccines since its inception; reporting volume is quantified by the program’s statistics page
- In the MMWR v-safe analysis, 79.0% of participants reported local reactions (such as pain) after the second dose; local reaction prevalence quantified by dose
- Vaccine safety monitoring systems expanded globally with active surveillance tools like CDC v-safe; v-safe enrollment reached 8.2 million participants as of reporting; quantified on CDC’s site
- 1.0% of healthcare providers in a survey reported changing vaccination practices due to known side effects; survey quantifies behavior change
- 40% of respondents in a vaccine hesitancy survey cited concern about side effects as a reason for delaying vaccination; quantified in the study
- In a systematic review of vaccine side effects and health care use, the most common adverse events were local reactions (pain, redness) and systemic reactions (fever, fatigue) with most events resolving within 1–3 days; review quantifies typical duration distributions
Most vaccine side effects begin within a couple days, peak early, and resolve within about 1 to 3 days.
Related reading
01 · Category
Epidemiology And Risk17 stats
01
In safety communications for mRNA COVID-19 vaccines, most non-serious adverse reactions start within 1–2 days and resolve within about 1–3 days; timing distribution is summarized in clinical safety descriptions
02
In the Pfizer-BioNTech BNT162b2 clinical trial publication, participants’ symptoms generally resolved within 1–2 days after dose 2; duration is described in the safety section
03
In the Moderna mRNA-1273 clinical trial safety publication, the median onset of local and systemic reactogenicity after dose 2 was within 2 days; timing is described in the safety analysis
04
In a study of influenza vaccines in U.S. children, about 1.4% of vaccinated children reported medically attended events for fever within 1–2 days; event frequency quantified
05
A Vaccine Safety Datalink study estimated that febrile seizures occurred at a rate of approximately 27 per 100,000 person-years in the population and that vaccination increased the relative risk shortly after vaccination; study provides rates
06
In a cohort study, the risk of myocarditis after smallpox vaccination was estimated at roughly 1 per 10,000 vaccine recipients (rare but measurable); study quantifies incidence
07
A UK study on MMR vaccination reported that the risk of anaphylaxis was about 1.3 cases per 1 million doses; quantifies incidence
08
In postmarketing surveillance, the incidence of anaphylaxis after influenza vaccination in the UK was estimated at 1–2 cases per million doses; incidence quantified by surveillance studies
09
In a large Swedish cohort study, the rate of Guillain-Barré syndrome after seasonal influenza vaccination was about 1.7 per million vaccinated persons; study provides incidence estimates
10
In an Ontario-based study of pertussis-containing vaccines, the incidence of severe allergic reactions was approximately 0.2 per 100,000 doses; study quantifies rare serious reactions
11
CDC’s Brighton Collaboration surveillance report states that febrile seizures following MMR vaccination are uncommon with estimated rates on the order of 1 per 3,000–4,000 doses; estimates are provided in the summary
12
In a meta-analysis of systemic reactions, fatigue was reported at approximately 40–60% across mRNA vaccine trial datasets (pooled); quantifies common systemic reactions
13
In an assessment of COVID-19 vaccine adverse event reporting, the median time from vaccination to reported myocarditis onset was around 3–4 days in multiple studies; quantified in a pooled analysis
14
In a US claims analysis of vaccine adverse events, 80%+ of non-serious adverse events were short duration (typically within a few days); quantified in the analysis summary
15
In a US study of vaccine safety communications, 70% of respondents reported that they had access to side-effect information in a timely way; survey quantifies exposure to information
16
In the US VSD study of COVID-19 vaccine reactogenicity, the risk of medically attended adverse events was low; the study provides absolute rates by outcome
17
In EMA’s periodic safety update summaries for COVID-19 vaccines, millions of doses were reviewed and millions of people were vaccinated during safety monitoring; EMA summarizes total exposure by country/period
Interpretation
Epidemiology And Risk Interpretation
For the epidemiology and risk angle, the data across vaccine types show that side effects are often time-limited with most mRNA COVID-19 reactions beginning within 1 to 2 days and lasting about 1 to 3 days, while rarer risks like febrile seizures occur at about 27 per 100,000 person-years and myocarditis after smallpox vaccination is estimated at roughly 1 per 10,000 recipients.
02 · Category
Serious Adverse Events4 stats
01
In CDC’s surveillance, the reporting rate of myocarditis after dose 2 was 19.3 per million second doses in males aged 18–24 years (as provided in CDC tables)
02
In the Vaccine Safety Datalink (VSD) analysis, the observed risk of febrile seizures was highest in the first 1–2 days after vaccination; febrile seizure risk windows were quantified in the study
03
In a large cohort study of influenza vaccination, Guillain-Barré syndrome occurred at a rate of about 1–2 cases per 1 million vaccinated in the evaluated periods; study quantified excess risk
04
In the NEJM Danish study, the incidence rate of TTS after vaccination with ChAdOx1 nCoV-19 was estimated at 15.1 per million person-months during the risk window; the incidence is quantified
Interpretation
Serious Adverse Events Interpretation
Across major surveillance and cohort studies, serious adverse events are uncommon but show clear timing and demographic patterns, including myocarditis at 19.3 per million second doses in males aged 18 to 24 and TTS after ChAdOx1 at 15.1 per million person-months, which underscores why serious-event monitoring focuses on who gets vaccinated and when symptoms appear.
03 · Category
Reporting And Pharmacovigilance2 stats
01
VAERS (US) reported more than 1.8 million adverse event reports for vaccines since its inception; reporting volume is quantified by the program’s statistics page
02
In the MMWR v-safe analysis, 79.0% of participants reported local reactions (such as pain) after the second dose; local reaction prevalence quantified by dose
Interpretation
Reporting And Pharmacovigilance Interpretation
Under reporting and pharmacovigilance, VAERS has amassed over 1.8 million vaccine adverse event reports since its inception, and the v-safe analysis shows that 79.0% of participants reported local reactions after the second dose, underscoring both the scale of ongoing safety monitoring and the commonness of certain effects in systematic reporting.
More related reading
04 · Category
Industry Trends6 stats
01
Vaccine safety monitoring systems expanded globally with active surveillance tools like CDC v-safe; v-safe enrollment reached 8.2 million participants as of reporting; quantified on CDC’s site
02
1.0% of healthcare providers in a survey reported changing vaccination practices due to known side effects; survey quantifies behavior change
03
40% of respondents in a vaccine hesitancy survey cited concern about side effects as a reason for delaying vaccination; quantified in the study
04
1.6 billion people worldwide received at least one dose of a COVID-19 vaccine by mid-2021; exposure scale affects side-effect surveillance
05
In a survey of pharmacovigilance professionals, 75% reported that digital signal detection tools improved their ability to identify safety signals; survey quantifies adoption/impact
06
In a report on immunization safety practices, 95% of surveyed jurisdictions had established vaccine adverse event reporting mechanisms; quantifies readiness in immunization programs
Interpretation
Industry Trends Interpretation
Industry trends show that as global vaccination scaled to 1.6 billion people receiving at least one COVID-19 dose by mid 2021, vaccine safety practices increasingly relied on active and digital monitoring, with 95% of jurisdictions having adverse event reporting mechanisms and 75% of pharmacovigilance professionals saying digital signal detection tools improved their ability to spot safety signals.
05 · Category
Clinical Trial Frequency1 stats
01
In a systematic review of vaccine side effects and health care use, the most common adverse events were local reactions (pain, redness) and systemic reactions (fever, fatigue) with most events resolving within 1–3 days; review quantifies typical duration distributions
Interpretation
Clinical Trial Frequency Interpretation
In the clinical trial frequency data, the most common adverse events were local reactions such as pain and redness, showing that these symptoms occur more often than other side effects across trials.
report visual · Breakdown
Vaccine side effects: when they start and how long they last
Most non-serious vaccine side effects tend to appear quickly after vaccination and resolve within a few days.
60%
In a meta-analysis of systemic reactions, fatigue was reported at approximately 40–60% across mRNA vaccine trial dataset
40%
40% of respondents in a vaccine hesitancy survey cited concern about side effects as a reason for delaying vaccination;
source-verifiedncbi.nlm.nih.gov
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Lukas Bauer. (2026, February 13). Vaccine Side Effects Statistics. Gitnux. https://gitnux.org/vaccine-side-effects-statistics
MLA
Lukas Bauer. "Vaccine Side Effects Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/vaccine-side-effects-statistics.
Chicago
Lukas Bauer. 2026. "Vaccine Side Effects Statistics." Gitnux. https://gitnux.org/vaccine-side-effects-statistics.
Sources & references
30 datasets cited across this report · attribution is report-level
+17 additional datasets cited (not shown individually)